Welcome to the e-CCO Library!

search
Search by: 
Year: Category:
Diverting stoma is enough!
Year: 2019
Source: 8th S-ECCO IBD Masterclass
Authors: Dieter Hahnloser
Created: Wednesday, 5 June 2019, 9:01 PM
Diverting stoma is enough!
Year: 2019
Source: 8th S-ECCO IBD Masterclass
Authors: Dieter Hahnloser
Created: Tuesday, 28 May 2019, 3:32 PM
Ileo anal pouch procedure, Stoma
Files: 1
Do guidelines prevent patient-centred care (Tandem Talk)
Year: 2021
Source: 2nd Guideline Methodology and GRADE Workshop
Authors: Susanna Jäghult, Hannah Gordon
Created: Friday, 1 October 2021, 12:41 PM
Summary content

1. To understand the background and benefits of Patient centered care

2. To review the evidence of Patient centered care

3. To learn about both benefits and disadvantages with patient involvement when developing guidelines

Do i really need a histopathologist?
Year: 2020
Source: 5th H-ECCO IBD Masterclass
Authors: James Lindsay
Created: Tuesday, 23 June 2020, 5:40 PM
Do i really need a histopathologist?
Year: 2020
Source: 5th H-ECCO IBD Masterclass
Authors: James Lindsay
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1
Do we still need RCTs? (Tandem Talk)
Year: 2021
Source: 4th School for Clinical Trialists
Authors: Geert D'Haens, Uri Kopylov
Created: Friday, 1 October 2021, 12:41 PM
Does size matter? How long should the Pouch be?
Year: 2018
Source: 7th S-ECCO IBD Masterclass
Authors: Colombo Francesco
Created: Tuesday, 8 May 2018, 11:36 AM
Files: 1
DOP001: Effectiveness and safety of vedolizumab in anti-TNF naïve patients with inflammatory bowel disease: a multicentre retrospective European Crohn’s and Colitis Organisation study
Year: 2018
Source: ECCO '18 Vienna
Authors:

U. Kopylov1*, B. Verstockt2, L. Biedermann3, S. Sebastian4, D. Pugliese5, E. Sonnenberg6, P.R. Steinhagen6, N. Arebi7, Y. Ron8, T. Kucharzik9, X. Roblin10, B. Ungar1, A. Bar-Gil Shitrit11, S. Ardizzone12, P. Molander13, M. Coletta14, L. Peyrin-Biroulet15, P. Bossuyt16, I. Avni-Biron17, E.I. Tsoukal18, M. Allocca19, K. Katsanos20, T. Raine21, T. Sipponen22, G. Fiorino23, S. Ben-Horin1, R. Eliakim1, A. Armuzzi5, B. Siegmund6, D.C. Baumgart6, N. Kamperidis7, N. Maharshak8, C. Maaser9, G. Mantzaris18, H. Yanai17, D. Christodoulou20, I. Dotan17, M. Ferrante2

Created: Thursday, 21 February 2019, 9:14 AM
DOP001: Effectiveness and safety of vedolizumab in anti-TNF naïve patients with Inflammatory Bowel Disease - a multicentre retrospective study
Year: 2018
Source: ECCO'18 Vienna
Authors: Kopylov Uri
Created: Tuesday, 8 May 2018, 11:36 AM
Files: 1
DOP001: European Crohn's and Colitis Organisation topical review on environmental factors in IBD
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Maaser C.*1, Langholz E.2, Gordon H.3, Burisch J.4, Ellul P.5, Hernández V.6, Karakan T.7, Katsanos K.H.8, Krustins E.9, Levine A.10, Mantzaris G.J.11, O'Morain C.12, Yuksel E.S.13, Strid H.14, Annese V.15

Created: Wednesday, 20 February 2019, 10:36 AM
DOP001: European Crohn’s and Colitis Organisation topical review on environmental factors in IBD
Year: 2017
Source: ECCO'17 Barcelona
Authors: Maaser C.
Environmental factors, Microbiota, Smoking
Files: 1
DOP001: Genetic and environmental risk model to predict intestinal inflammation in asymptomatic first-degree relatives of Crohn’s disease patients
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

K. M. Taylor*1, 2, N.S. Taylor3, S. H. Anderson1, P. M. Irving1, N. J. Prescott2, C. M. Lewis2, C. G. Mathew2, J. D. Sanderson1

Created: Friday, 22 February 2019, 9:49 AM
DOP001: Genetic and environmental risk model to predict intestinal inflammation in asymptomatic first-degree relatives of Crohn’s disease patients
Year: 2016
Source: ECCO'16 DOP
Authors: Taylor K.
calprotectin, capsule endoscopy, Crohn's Disease, genetics
Files: 1
DOP002: Molecular response to ustekinumab in moderate-to-severe Crohn’s disease by serum protein analysis: results from the UNITI-1 and UNITI-2 Phase 3 induction studies
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

K. Li*, K. Hayden, E. Wadman, S. Bhagat, S. Emrich, J. R. Friedman, C. Gasink, C. Brodmerkel

Created: Friday, 22 February 2019, 9:49 AM
DOP002: Molecular Response to Ustekinumab in Moderate-to-Severe Crohn’s Disease by Serum Protein Analysis: Results from the UNITI-1 and UNITI-2 Phase 3 Induction Studies
Year: 2016
Source: ECCO'16 DOP
Authors: Li K.
Crohn's Disease, ustekinumab, immunology
Files: 1
DOP002: Trends in small bowel resections for Crohn's disease with and without short bowel syndrome in the era of biologics
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Limketkai B.1, Parian A.2, Colombel J.-F.*3

Created: Wednesday, 20 February 2019, 10:36 AM
DOP002: Trends in small bowel resections for Crohn’s disease with and without short bowel syndrome in the era of biologics
Year: 2017
Source: ECCO'17 Barcelona
Authors: Colombel J.
Natural history
Files: 1
DOP002: Vedolizumab treatment persistence up to 3 years: post hoc analysis in vedolizumab-naïve patients from the GEMINI LTS study
Year: 2018
Source: ECCO '18 Vienna
Authors:

S. Vermeire1*, E.V. Loftus Jr.2, J.M. Khalid3, D. Tudor4, M. Akbari5, D. Demuth3, L. Peyrin-Biroulet6

Created: Thursday, 21 February 2019, 9:14 AM
DOP002:Vedolizumab treatment persistence up to 3 years: Post hoc analysis in vedolizumab-naïve patients from the GEMINI LTS study
Year: 2018
Source: ECCO'18 Vienna
Authors: Vermeire Séverine
Created: Tuesday, 8 May 2018, 11:36 AM
Files: 1
DOP003: Gene expression profiling indicates similar molecular pathways are active in adult and paediatric ulcerative colitis
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

K. Li*1, J. Ouahed2, J. Friedman1, R. Strauss1, D. Chan1, S. Telesco1, D. Shouval3, J. Canavan4, C. Brodmerkel1, S. Snapper5

Created: Friday, 22 February 2019, 9:49 AM